Mechanism of action for NNZ-2566 anti-inflammatory effects following PBBI involves upregulation of immunomodulator ATF3. - Wikidata - wikimedia - TriplyDB

Mechanism of action for NNZ-2566 anti-inflammatory effects following PBBI involves upregulation of immunomodulator ATF3.

Mechanism of action for NNZ-2566 anti-inflammatory effects following PBBI involves upregulation of immunomodulator ATF3.

http://www.wikidata.org/entity/Q34350748

about

Emerging pharmacologic treatment options for fragile X syndrome Fragile X targeted pharmacotherapy: lessons learned and future directions.Improving Treatment Trial Outcomes for Rett Syndrome: The Development of Rett-specific Anchors for the Clinical Global Impression Scale Retracted: Nrf2: a novel therapeutic target in fragile X syndrome is modulated by NNZ2566.The role for IGF-1-derived small neuropeptides as a therapeutic target for neurological disorders.Treatment of traumatic brain injury with anti-inflammatory drugs.Pharmacotherapy for Fragile X Syndrome: Progress to Date.Microglial Inflammasome Activation in Penetrating Ballistic-like Brain Injury.

P2860

Q26829152-F6379672-B95F-4310-BEAC-5E4D46DA1034 Q33785983-9432F947-52AF-4803-A26A-645A3B74D67F Q36176918-0AA83A0F-3913-4BF7-8012-023693D9A0CB Q36283892-927D8C7C-39C1-41FD-B70A-1F90B833F873 Q38344573-AF7D8716-6567-4F7E-8F94-5CFD11A1CB54 Q38538072-8AD9A683-5FE3-4683-AC09-256C489C49CC Q38726962-0394CC32-969A-4587-8DC9-014C3FFF1F64 Q50033561-BE8A91A5-9933-4828-A4A5-6E658D4DC29C

P2860

Mechanism of action for NNZ-2566 anti-inflammatory effects following PBBI involves upregulation of immunomodulator ATF3.

http://www.wikidata.org/entity/Q34350748

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Mechanism of action for NNZ-25 ...... ation of immunomodulator ATF3.

@ast

Mechanism of action for NNZ-25 ...... ation of immunomodulator ATF3.

@en

Mechanism of action for NNZ-25 ...... ation of immunomodulator ATF3.

@nl

type

label

Mechanism of action for NNZ-25 ...... ation of immunomodulator ATF3.

@ast

Mechanism of action for NNZ-25 ...... ation of immunomodulator ATF3.

@en

Mechanism of action for NNZ-25 ...... ation of immunomodulator ATF3.

@nl

prefLabel

Mechanism of action for NNZ-25 ...... ation of immunomodulator ATF3.

@ast

Mechanism of action for NNZ-25 ...... ation of immunomodulator ATF3.

@en

Mechanism of action for NNZ-25 ...... ation of immunomodulator ATF3.

@nl

P1433

Q34350748-B919DEAB-B92A-4DDE-872F-213BAAC46BEB

P1476

Q34350748-4725FD3C-C495-47D5-B735-7DAB2B3DD644

P2093

Q34350748-1D86D128-CDC4-4F9D-900B-FC5505D2584B

Q34350748-231C899E-6242-44A6-8DAF-0E586B765D91

Q34350748-45815E6B-0D5C-4654-8871-699BBBDDCC9A

Q34350748-50E3CCCE-9602-4D9B-BBFF-6F8B95E6E9F8

Q34350748-5719C6BB-E598-47BF-B144-A6A15C258BAA

Q34350748-6BC5F0A1-87BC-40A1-8082-36E6ED78F66F

Q34350748-92ABB765-3B3B-43C6-A590-4C56D342C748

P2860

Q34350748-09AB700C-996E-48AE-8847-106034858833

Q34350748-10A6B1D9-5A66-4DA0-B439-877FE8A30705

Q34350748-11488166-898F-4DC2-833C-9E0EC590591D

Q34350748-17479C3E-66C8-47ED-AD1B-19E6F0B0F5CF

Q34350748-1EB46A4A-236E-48B0-B30B-8EAFC5645DFF

Q34350748-284750CA-9FB6-4937-A5D9-DE8D94225964

Q34350748-29618B60-1E7C-4FD1-A8A8-7A36A5CD3A8C

Q34350748-372B5677-2046-4E5C-9BE8-B6FCC352C4E5

Q34350748-3D9865F9-7DB9-4F9D-87C6-816C8D3097AD

Q34350748-43BE58EB-3F19-4DE1-94D7-2F6F03AB6064

P2888

Q34350748-D1B36200-234E-475F-90B9-4001EF4D83BA

P304

Q34350748-80B7C568-18DF-4E15-B6AF-0BBB575356CE

P31

Q34350748-0C510528-BFF4-499C-803C-6E8AE4FC9740

P356

Q34350748-6B3DA1C4-FFA4-434C-96A1-89C23E063467

P433

Q34350748-352183B3-FCEF-49D6-AEB4-B91B33B476D3

P478

Q34350748-A5032E3E-9EA9-4434-9B11-458648C31EC7

P577

Q34350748-CC55424E-9425-4850-A693-AF715786E460

P6179

Q34350748-C5898709-0C29-4179-97CF-343BE3FB9D76

P698

Q34350748-E0E877B4-AB54-4A2D-A12D-5A10986BB063

P356

S12017-013-8236-Z

P1433

NeuroMolecular Medicine

P1476

Mechanism of action for NNZ-25 ...... ation of immunomodulator ATF3.

@en

P2093

Casandra M Cartagena

http://www.w3.org/2001/XMLSchema#string

Frank C Tortella

http://www.w3.org/2001/XMLSchema#string

Garry L Williams

http://www.w3.org/2001/XMLSchema#string

Jitendra R Dave

http://www.w3.org/2001/XMLSchema#string

Kara E Schmid

http://www.w3.org/2001/XMLSchema#string

Katie L Phillips

http://www.w3.org/2001/XMLSchema#string

Melissa Konopko

http://www.w3.org/2001/XMLSchema#string

P2860

CD8+ T Cell Effector Mechanisms in Resistance to Infection

Gamma oscillations in the auditory cortex of awake rats

Regulation of human NK-cell cytokine and chemokine production by target cell recognition.

A signaling cascade of nuclear calcium-CREB-ATF3 activated by synaptic NMDA receptors defines a gene repression module that protects against extrasynaptic NMDA receptor-induced neuronal cell death and ischemic brain damage.

Immune function of astrocytes.

An alpha-syntrophin-dependent pool of AQP4 in astroglial end-feet confers bidirectional water flow between blood and brain

NNZ-2566: a Gly-Pro-Glu analogue with neuroprotective efficacy in a rat model of acute focal stroke.

Astrocytes and brain injury.

T-cell cytokines in injury-induced neural damage and repair.

Role of astrocytes in glutamate homeostasis: implications for excitotoxicity.

P2888

s12017-013-8236-z

P304

504-514

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12017-013-8236-Z

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2013-06-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1028675892

http://www.w3.org/2001/XMLSchema#string

P698

23765588

http://www.w3.org/2001/XMLSchema#string